HLB Genex, Inc. Logo

HLB Genex, Inc.

Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.

187420 | KO

Overview

Corporate Details

ISIN(s):
KR7187420005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노1로 65(관평동), 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HLB Genex, Inc. is a biotechnology company specializing in the development and production of customized enzymes and microbiome-based solutions. The company leverages proprietary R&D platforms, including Microbial Surface Display Technology for high-throughput screening and Recombinant Protein Expression for scalable manufacturing. Its product portfolio consists of industrial special enzymes, such as Lactase, Catalase, and Proteinase K used in molecular diagnostics, and bio-healthcare ingredients like Vitamin K2 and Phytosphingosine for nutritional and cosmetic applications. HLB Genex is also actively engaged in the research and development of microbiome therapeutics by discovering and engineering effector molecules from beneficial microorganisms.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Capital/Financing Update
주권관련사채권의취득결정
Korean 37.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-07-07 00:00
Share Issue/Capital Change
전환가액의조정
Korean 12.7 KB
2025-07-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 13.3 KB
2025-06-30 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 18.3 KB
2025-06-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.6 KB
2025-06-10 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-05-21 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 25.4 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.8 MB
2025-05-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-04-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 240.1 KB
2025-04-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 239.0 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-04-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 239.0 KB

Automate Your Workflow. Get a real-time feed of all HLB Genex, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Genex, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Genex, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO
Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN

Talk to a Data Expert

Have a question? We'll get back to you promptly.